These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 16389646

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH.
    Chin Med J (Engl); 2006 May 20; 119(10):814-21. PubMed ID: 16732983
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism.
    Qi W, Chen X, Zhang Y, Holian J, Mreich E, Gilbert RE, Kelly DJ, Pollock CA.
    Nephrol Dial Transplant; 2007 Nov 20; 22(11):3147-53. PubMed ID: 17664181
    [Abstract] [Full Text] [Related]

  • 26. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
    Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M.
    Am J Physiol Renal Physiol; 2006 Apr 20; 290(4):F813-20. PubMed ID: 16278277
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T, Takemura G, Kosai K, Ohno T, Takahashi T, Esaki M, Goto K, Maruyama R, Murata I, Minatoguchi S, Fujiwara T, Fujiwara H.
    Clin Exp Pharmacol Physiol; 2008 Nov 20; 35(11):1288-93. PubMed ID: 18505441
    [Abstract] [Full Text] [Related]

  • 29. Protease administration decreases enhanced transforming growth factor-beta 1 content in isolated glomeruli of diabetic rats.
    Paczek L, Gaciong Z, Bartlomiejczyk I, Sebekova K, Birkenmeier G, Heidland A.
    Drugs Exp Clin Res; 2001 Nov 20; 27(4):141-9. PubMed ID: 11822224
    [Abstract] [Full Text] [Related]

  • 30. [Effects of lovastatin on renal function and expression of phosphorylating-p38 mitogen-activated protein kinase in experimental diabetic nephropathy in rats].
    Wang LH, Duan HJ, Shi YH, Liu QJ, He N, Liu SX.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Dec 20; 16(12):734-7. PubMed ID: 15585148
    [Abstract] [Full Text] [Related]

  • 31. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):264-71. PubMed ID: 18582458
    [Abstract] [Full Text] [Related]

  • 32. Impact of renal denervation on renal content of GLUT1, albuminuria and urinary TGF-beta1 in streptozotocin-induced diabetic rats.
    D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H.
    Auton Neurosci; 2003 Mar 28; 104(2):88-94. PubMed ID: 12648610
    [Abstract] [Full Text] [Related]

  • 33. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
    Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA.
    Kidney Int; 2005 Apr 28; 67(4):1297-307. PubMed ID: 15780082
    [Abstract] [Full Text] [Related]

  • 34. [The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy].
    Xu JY, Tao LJ, Wang L, Ning WB, Liu JS.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep 28; 33(9):836-40. PubMed ID: 18812664
    [Abstract] [Full Text] [Related]

  • 35. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes.
    D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H.
    Horm Metab Res; 2001 Nov 28; 33(11):664-9. PubMed ID: 11733869
    [Abstract] [Full Text] [Related]

  • 36. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice.
    Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A.
    J Endocrinol; 2006 Mar 28; 188(3):493-501. PubMed ID: 16522729
    [Abstract] [Full Text] [Related]

  • 37. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P, Eiam-Ong S, Suwanwalaikorn S.
    J Med Assoc Thai; 2006 Feb 28; 89(2):170-7. PubMed ID: 16579002
    [Abstract] [Full Text] [Related]

  • 38. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
    Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y.
    Nephrology (Carlton); 2006 Feb 28; 11(1):29-35. PubMed ID: 16509929
    [Abstract] [Full Text] [Related]

  • 39. Urinary transforming growth factor-beta(1), collagen IV and the effect of insulin in children at diagnosis of diabetes mellitus.
    Holmquist P, Torffvit O.
    Scand J Urol Nephrol; 2009 Feb 28; 43(2):142-7. PubMed ID: 18979373
    [Abstract] [Full Text] [Related]

  • 40. Protective effect of Gui Qi mixture on the progression of diabetic nephropathy in rats.
    Zhang YW, Xie D, Chen YX, Zhang HY, Xia ZX.
    Exp Clin Endocrinol Diabetes; 2006 Nov 28; 114(10):563-8. PubMed ID: 17177138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.